[1]程伟宁,黄 荣,张 锐,等.帕金森病患者血清miR-497-5p，FGF2和BDNF表达水平与认知功能障碍的相关性[J].现代检验医学杂志,2025,40(04):121-126.[doi:10.3969/j.issn.1671-7414.2025.04.021]
　CHENG Weining,HUANG Rong,ZHANG Rui,et al.Correlation between Serum miR-497-5p，FGF2 and BDNF Expression Levels with Cognitive Dysfunction in Parkinson’s Disease Patients[J].Journal of Modern Laboratory Medicine,2025,40(04):121-126.[doi:10.3969/j.issn.1671-7414.2025.04.021]
点击复制

帕金森病患者血清miR-497-5p，FGF2和BDNF表达水平与认知功能障碍的相关性()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年04期
页码:
121-126
栏目:
论著
出版日期:
2025-07-15

文章信息/Info

Title:
Correlation between Serum miR-497-5p，FGF2 and BDNF Expression Levels with Cognitive Dysfunction in Parkinson’s Disease Patients
文章编号:
1671-7414（2025）04-121-06
作者:
程伟宁，黄 荣，张 锐，谭登云
（武汉市新洲区人民医院神经内科，武汉 430400）
Author(s):
CHENG Weining，HUANG Rong，ZHANG Rui，TAN Dengyun
(Department of Neurology，Wuhan Xinzhou District People’s Hospital，Wuhan 430400, China)
关键词:
帕金森病; 微小核糖核酸-497-5p; 成纤维细胞生长因子-2; 脑源性神经营养因子; 认知功能障碍
分类号:
R744.8
DOI:
10.3969/j.issn.1671-7414.2025.04.021
文献标志码:
A
摘要:
目的 探究血清微小RNA （micro RNA，miR）-497-5p，成纤维细胞生长因子-2（FGF2）、脑源性神经营养因子（BDNF）水平与帕金森病（PD）患者认知功能障碍的关系。方法 选取2022 年4 月～ 2024 年4 月武汉市新洲区人民医院治疗的PD 患者86 例（研究组）与健康体检者60 例（对照组），采用实时荧光聚合酶链反应（RT-qPCR）测定血清miR-497-5p 水平，采用酶联免疫吸附试验（ELISA）测定血清FGF2，BDNF 水平；Spearman 分析血清miR-497-5p，FGF2，BDNF 水平与蒙特利尔认知评估量表（MoCA）的相关性；Logistic 分析影响PD 患者并发认知功能障碍的因素；受试者工作特征（ROC）曲线分析血清miR-497-5p，FGF2，BDNF 对PD 患者并发认知功能障碍的诊断价值。结果 研究组血清miR-497-5p（2.73±0.67）表达水平与对照组（1.04±0.34）相比显著升高，研究组FGF2（1.94±0.45 ng/ml）、BDNF（8.31±2.44 ng/ml）表达水平与对照组相比（2.71±0.69 ng/ml，12.81±3.07 ng/ml）显著降低，差异具有统计学意义（t=17.977，8.161，9.850，均P<0.05）。血清miR-497-5p 与MoCA 评分呈负相关（r=-0.331，P<0.05），FGF2，BDNF 水平与MoCA 评分呈正相关（r=0.404，0.361，均P<0.05）。认知功能障碍组病程、miR-497-5p 水平显著高于认知功能正常组，FGF2，BDNF 水平、MoCA 评分显著低于认知功能正常组，差异具有统计学意义（t=2.350 ～ 11.792，均P<0.05）。PD 患者病程、血清miR-497-5p 是PD 患者认知功能障碍的危险因素（Waldχ2=4.712，5.704，均P<0.05）；MoCA评分、血清FGF2，BDNF 是PD 患者认知功能障碍的保护因素（Wald χ2=4.499，5.556，5.217，均P<0.05）。血清miR-497-5p，FGF2，BDNF 三者联合对PD 患者并发认知功能障碍的AUC（95%CI），敏感度高于单独诊断；血清miR-497-5p，FGF2，BDNF 三者联合对PD 患者并发认知功能障碍的诊断效果优于单独诊断，差异具有统计学意义（Z=2.279，2.236，2.123，均P<0.05）。结论 血清miR-497-5p 升高、FGF2，BDNF 水平降低会使PD 患者并发认知功能障碍的风险增加，三者联合对PD 患者并发认知功能障碍的诊断价值较好。
Abstract:
Objective To investigate the relationship between serum levels of micro RNA (miR)-497-5p, fibroblast growth factor-2 (FGF2) and brain-derived neurotrophic factor (BDNF), with cognitive dysfunction in Parkinson’s disease (PD) patients. Methods From April 2022 to April 2024, 86 PD patients (study group) treated in Wuhan Xinzhou District People’s Hospital and 60 healthy individuals (control group) who underwent physical examination in Wuhan Xinzhou District People’s Hospital were selected. Serum miR-497-5p levels were determined by real-time quantitative polymerase chain reaction (RT-qPCR), and serum FGF2 and BDNF levels were measured by enzyme linked immunosorbent assay (ELISA). Spearman was applied to analyze the correlation between serum miR-497-5p, FGF2, BDNF levels and montreal cognitive assessment (MoCA score). Logistic analysis was applied to analyze the factors influencing cognitive dysfunction in PD patients. Receiver operating characteristic (ROC) was applied to analyze the diagnostic value of serum miR-497-5p, FGF2 and BDNF for cognitive dysfunction in PD patients. Results The serum miR-497-5p (2.73±0.67) expression level in the study group was obviously increased than that in the control group (1.04±0.34), while the expression levels of FGF2 (1.94±0.45ng/ml) and BDNF (8.31±2.44ng/ml) were obviously reduced than those in the control group (2.71±0.69ng/ml, 12.81±3.07ng/ml), with significate differences (t=17.977, 8.161, 9.850, all P<0.05). Serum miR-497-5p was negatively correlated with MoCA score（r=-0.331， P<0.05）, while FGF2 and BDNF levels were positively correlated with MoCA score (r=0.404, 0.361, all P<0.05). Cognitive dysfunction group had significantly higher disease duration，FGF2, BDNF levels, and MoCA scores than the cognitively normal group.The course of disease and miR-497-5p levels in the cognitive dysfunction group were obviously higher than that in the normal cognitive function group, FGF2, BDNF levels, and MoCA scores in the cognitive dysfunction group were obviously lower than that in the normal cognitive function group (t=2.350 ～ 11.792，all P<0.05). The course of disease and serum miR- 497-5p were risk factors for cognitive dysfunction in PD patients（Wald χ2=4.712，5.704，all P<0.05）, while MoCA score, serum FGF2, and BDNF were protective factors for cognitive dysfunction in PD patients（Wald χ2=4.499，5.556，5.217，all P<0.05）. The AUC and sensitivity of the combination of serum miR-497-5p, FGF2, and BDNF in PD patients with cognitive impairment were higher than those of individual diagnosis. The diagnostic effect of the combination of miR-497-5p, FGF2, and BDNF in PD patients with cognitive dysfunction was better than that of individual diagnosis, and the differences were statistically significant（Z=2.279，2.236，2.123，all P<0.05）. Conclusion Elevated serum miR-497-5p level and decreased FGF2 and BDNF levels can increase the risk of cognitive dysfunction in PD patients, and the combination of the three has good diagnostic value for cognitive dysfunction in PD patients.

参考文献/References:

[1] PAJARES M, I ROJO A, MANDA G, et al. Inflammation in Parkinson’s disease：mechanisms and therapeutic implications[J]. Cells, 2020, 9(7): 1687.
[2] 郑德泉, 江华, 林锦标, 等. 帕金森病患者血清NPASDP-4, MBP 水平表达与认知功能障碍及严重程度的诊断价值研究[J]. 现代检验医学杂志, 2024, 39(3): 17-23, 59. ZHENG D Q, JIANG H, LIN J B, et al. Study on the diagnostic value of serum NPASDP-4 and MBP level expression with cognitive dysfunction and severity in Parkinson’s disease patients[J]. Journal of Modern Laboratory Medicine, 2024, 39(3): 17-23, 59.
[3] GOLDMAN J G, SIEG E. Cognitive impairment and dementia in parkinson disease[J]. Clinics in Geriatric Medicine, 2020, 36(2): 365-377.
[4] TOLOSA E, GARRIDO A, SCHOLZ S W, et al. Challenges in the diagnosis of Parkinson’s disease[J]. the Lancet Neurology, 2021, 20(5): 385-397.
[5] ZHU W J, ZHANG H, GAO J, et al. Silencing of miR-497-5p inhibits cell apoptosis and promotes autophagy in Parkinson’s disease by upregulation of FGF2[J]. Environmental Toxicology, 2021, 36(11): 2302-2312.
[6] ILIEVA M, NIELSEN T T, MICHEL T, et al. FGF2 and dual agonist of NCAM and FGF receptor 1, Enreptin,rescue neurite outgrowth loss in hippocampal neurons expressing mutated huntingtin proteins[J]. Journal of Neural Transmission (Vienna, Austria : 1996), 2019,126(11): 1493-1500.
[7] 岳刘平, 孙永康, 徐方飚, 等. 基于BDNF/TrkB 信号通路探讨中药调控阿尔茨海默病的研究进展[J].中国实验方剂学杂志,2024,30(20):274-282． YUE L P, SUN Y K, XU F B, et al. Regulation of Alzheimer’s disease by chinese medicine based on BDNF/TrkB signaling pathway: a review [J]. Chinese Journal of Experimental Traditional Medical Formulae,2024,30(20):274-282．
[8] CIESIELSKA N, SOKO?OWSKI R, MAZUR E, et al. Is the Montreal cognitive assessment (MoCA) test better suited than the Mini-mental state examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? meta-analysis[J]. Psychiatria Polska, 2016, 50(5): 1039-1052.
[9] 中华医学会神经病学分会帕金森病及运动障碍学组. 中国医师协会神经内科医师分会帕金森病及运动障碍专业. 中国帕金森病的诊断标准(2016 版)[J].中华神经科杂志,2016,49(4):268-271. Chinese Society of Parkinson’s Disease and Movement Disorders，Parkinson’s Disease and Movement Disorder Section of Neurologist Branch of Chinese Medical Doctor Association. Diagnostic criteria for Parkinson’s disease in China (2016 edition) [J]. Chinese Journal of Neurology, 2016, 49(4): 268-271.
[10] RAJAN S, KAAS B. Parkinson’s disease: risk factor modification and prevention[J]. Seminars in Neurology,2022, 42(5): 626-638.
[11] 马春潮, 朱晓冬. 帕金森病认知障碍[J]. 中国实用内科杂志, 2019, 39(9): 769-774. MA C C, ZHU X D. Parkinson’s disease with cognitive impairment[J]. Chinese Journal of Practical Internal Medicine, 2019, 39(9): 769-774.
[12] 张美美, 张玉梅. 帕金森痴呆标志物研究进展[J]. 中华老年心脑血管病杂志,2020,22(12):1342-1344. ZHANG M M, ZHANG Y M. Advances in Parkinson’s dementia marker research[J]. Chinese Journal of Geriatric Heart Brain and Vessel Diseases, 2020,22(12): 1342-1344.
[13] CHEN Q X, YAN J J, XIE W J, et al. LncRNA LINC00641 sponges miR-497-5p to ameliorate neural injury induced by anesthesia via up-regulating BDNF [J].Frontiers in Molecular Neuroscience, 2020, 13: 95.
[14] SUN L J, YUAN R．LncRNA SNHG12 ameliorates bupivacaine-induced neurotoxicity by sponging miR-497-5p to upregulate NLRX1 [J]. Human & Experimental Toxicology, 2022, 41: 9603271221089001.
[15] GONG C Y，HE X N，LI G L，et al. MiR-497-5p promoted neuronal injury in ischemic stroke by inhibiting the BDNF/TrkB/PI3K/Akt pathway [J]. General Physiology and Biophysics，2024，43(2): 175-183.
[16] WANG Z Y, WANG Z Y, WANG A Q, et al. The neuroprotective mechanism of sevoflurane in rats with traumatic brain injury via FGF2[J]. Journal of Neuroinflammation, 2022, 19(1): 51.
[17] YAN J N，ZHANG F P，NIU L，et al. Highfrequency repetitive transcranial magnetic stimulation mitigates depression-like behaviors in CUMS-induced rats via FGF2/FGFR1/p-ERK signaling pathway [J]. Brain Research Bulletin, 2022, 183: 94-103.
[18] CHOI G E, CHAE C W, PARK M R, et al. Prenatal glucocorticoid exposure selectively impairs neuroligin 1-dependent neurogenesis by suppressing astrocytic FGF2-neuronal FGFR1 axis [J]. Cellular and Molecular Life Sciences, 2022, 79(6): 294.
[19] 高嘉潞, 王鑫, 宋甜甜, 等. 脑源性神经营养因子在阿尔茨海默病治疗中进展[J]. 中国老年学杂志,2022,42(23):5889-5892. GAO J L, WANG X, SONG T T, et al. Advances in brain-derived neurotrophic factor in the treatment of Alzheimer’s disease[J]. Chinese Journal of Gerontology, 2022, 42(23): 5889-5892.
[20] 苏利梅, 李德瑜, 陈小芳, 等. 岭南头皮针对气虚血瘀型卒中后认知功能障碍患者BDNF, IL-6 及认知功能的影响[J]. 中华中医药学刊,2024,42(12):219-223. SU L M, LI D Y, CHEN X F, et al. Effects of Lingnan scalp on serum brain-derived neurotrophic factor,interleukin-6 and cognitive function in patients with post-stroke cognitive impairment of qi deficiency and blood stasis type [J]. Chinese Archives of Traditional Chinese Medicine,2024,42(12):219-223．
[21 闫桂柳, 郭旺, 杨雪萍, 等. 脑卒中后抑郁大鼠海马星形胶质细胞脑源性神经营养因子及其受体的表达变化[J]. 中华老年心脑血管病杂志,2023,25(4):425-428. YAN G L, GUO W, YANG X P, et al. Expression of brain-derived neurotrophic factor and its receptor in hippocampal astrocytes of post-stroke depression rats[J]. Chinese Journal of Geriatric Heart Brain and Vessel Diseases, 2023, 25(4): 425-428.
[22] 高源, 朱金华, 张媛, 等. 温胆汤对精神分裂症模型大鼠海马组织BDNF,CaMK Ⅱ表达的影响[J]. 中药药理与临床,2021,37(4):8-12. GAO Y, ZHU J H, ZHANG Y, et al. Effects of Wendan decoction on BDNF and CaM K Ⅱ expression in hippocampus of Schizophrenia model rats[J]. Pharmacology and Clinics of Chinese Materia Medica, 2021, 37(4): 8-12.

相似文献/References:

[1]武 琪,陈 亮,张宝华.帕金森病患者血清和脑脊液褪黑素水平变化及其临床意义[J].现代检验医学杂志,2017,32(05):90.[doi:10.3969/j.issn.1671-7414.2017.05.017]
　WU Qi,CHEN Liang,ZHANG Bao-hua.Changes and Clinical Significance of Melatonin in Blood and Cerebrospinal Fluid of Patients with Parkinson's Disease[J].Journal of Modern Laboratory Medicine,2017,32(04):90.[doi:10.3969/j.issn.1671-7414.2017.05.017]
[2]武 琪,张宝华.Nrf2基因启动子-653G/A,-651G/A和-617C/A位点单核苷酸多态性与帕金森病易感性的关联性研究[J].现代检验医学杂志,2017,32(06):60.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　WU Qi,ZHANG Bao-hua.Association between Nrf2 Gene -653G/A,-651G/A and -617C/A Polymorphism and Susceptibility of Parkinson's Disease[J].Journal of Modern Laboratory Medicine,2017,32(04):60.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[3]李泽东,詹　贞,刘　忆,等.帕金森病患者血清鳞状细胞癌抗原（SCC-Ag）表达的临床意义[J].现代检验医学杂志,2019,34(06):70.[doi:10.3969 ／ j.issn.1671-7414.2019.06.017]
　LI Ze-dong,ZHAN Zhen,LIU Yi,et al.Significance of SCC Antigen Expression in Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2019,34(04):70.[doi:10.3969 ／ j.issn.1671-7414.2019.06.017]
[4]尚天明,毕开湘.唾液 α- 突触核蛋白 (SNCA) 与嗅觉评估在帕金森病早期筛查中的应用研究[J].现代检验医学杂志,2020,35(06):95.[doi:doi:10.3969/j.issn.1671-7414.2020.06.023]
　SHANG Tian-ming,BI Kai-xiang.Application Research of Olfactory Assessment and Salivary SNCA in EarlyScreening of Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2020,35(04):95.[doi:doi:10.3969/j.issn.1671-7414.2020.06.023]
[5]李群英,甄时建,何树光,等.帕金森病患者治疗期间血清miR-153，miR-128b水平表达与非运动症状的相关性研究[J].现代检验医学杂志,2021,36(05):120.[doi:10.3969/j.issn.1671-7414.2021.05.027]
　LI Qun-ying,ZHEN Shi-jian,HE Shu-guang,et al.Research on Correlation between Expression of Serum miR-153, miR-128bLevels and Non-motor Symptoms in Patients with Parkinson’s DiseaseDuring Treatment Period[J].Journal of Modern Laboratory Medicine,2021,36(04):120.[doi:10.3969/j.issn.1671-7414.2021.05.027]
[6]闫　欣,商素亮,李　娜,等.血浆S1P和HDL-C表达水平与帕金森病患者临床症状的相关性研究[J].现代检验医学杂志,2022,37(03):182.[doi:10.3969/j.issn.1671-7414.2022.03.038]
　YAN Xin,SHANG Su-liang,LI Na,et al.Correlation between Plasma S1P, HDL-C Expressions Levels and Clinical Symptoms in Patients with Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2022,37(04):182.[doi:10.3969/j.issn.1671-7414.2022.03.038]
[7]白 雪,董巧云,赵 丽,等.帕金森病患者血清miR-7 和α-Syn 表达水平与认知功能障碍的相关性研究[J].现代检验医学杂志,2023,38(04):78.[doi:10.3969/j.issn.1671-7414.2023.04.014]
　BAI Xue,DONG Qiaoyun,ZHAO Li,et al.Correlation between Serum miR-7 and α-Syn Expression Levels and Cognitive Impairment in Patients with Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2023,38(04):78.[doi:10.3969/j.issn.1671-7414.2023.04.014]
[8]郑德泉,江 华,林锦标,等.帕金森病患者血清NPASDP-4，MBP 水平表达与认知功能障碍及严重程度的诊断价值研究[J].现代检验医学杂志,2024,39(03):17.[doi:10.3969/j.issn.1671-7414.2024.03.003]
　ZHENG Dequan,JIANG Hua,LIN Jinbiao,et al.Study on the Diagnostic Value of Serum NPASDP-4 and MBP Level Expression with Cognitive Dysfunction and Severity in Parkinson’s Disease Patients[J].Journal of Modern Laboratory Medicine,2024,39(04):17.[doi:10.3969/j.issn.1671-7414.2024.03.003]
[9]牛荣荣,宋世雄,宋 蕾.帕金森病患者血清FGF22 和CXCL16 水平检测对认知障碍的诊断价值[J].现代检验医学杂志,2024,39(03):152.[doi:10.3969/j.issn.1671-7414.2024.03.026]
　NIU Rongrong,SONG Shixiong,SONG Lei.Diagnostic Value of Serum FGF22 and CXCL16 Levels in Patients with Parkinson’s Disease for Cognitive Impairment[J].Journal of Modern Laboratory Medicine,2024,39(04):152.[doi:10.3969/j.issn.1671-7414.2024.03.026]
[10]曹明月,王 巍,周美宁.LPIN1/PPARA 通过抑制SLC47A1 介导的神经元铁死亡缓解帕金森病模型大鼠病情进展的机制研究[J].现代检验医学杂志,2024,39(04):63.[doi:10.3969/j.issn.1671-7414.2024.04.012]
　CAO Mingyue,WANG Wei,ZHOU Meining.Mechanism Study on LPIN1/PPARA Alleviating the Progression of Parkinson’s Disease in Rats by Inhibiting SLC47A1-Mediated Ferroptosis of Neurons[J].Journal of Modern Laboratory Medicine,2024,39(04):63.[doi:10.3969/j.issn.1671-7414.2024.04.012]

备注/Memo

备注/Memo:
基金项目：湖北省卫生健康科研项目（WJ2022M053）。
作者简介：程伟宁（1975-）女，本科，副主任医师，研究方向：脑血管病及帕金森病，E-mail：chengwn066@163.com。
更新日期/Last Update: 2025-07-15